PDS Biotechnology said Phase 2 results for its HPV16-targeted immunotherapy PDS0101 plus pembrolizumab were published in JAMA Oncology. The company is now prioritizing PDS0301 in metastatic colorectal cancer and seeking partners for PDS0101.
published
PDS Biotechnology said Phase 2 results for its HPV16-targeted immunotherapy PDS0101 plus pembrolizumab were published in JAMA Oncology. The company is now prioritizing PDS0301 in metastatic colorectal cancer and seeking partners for PDS0101.
Latest documented BWB result
$APP market result
Exit $APP Sold Puts for a nice profit and then sold more Puts - this time the $325's for $3.97
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.